MAPT and Alzheimer disease: Everolimus and temsirolimus, rapamycin analogues and selective mTORC1 inhibitors, have also been studied for their potential neuroprotective effects in AD, due to their ability to enhance autophagy, reduce Aβ accumulation, and alleviate tau pathology [65,66].